These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17238227)

  • 21. Participation and crowd-out in a Medicare drug benefit: simulation estimates.
    Shea DG; Stuart BC; Briesacher B
    Health Care Financ Rev; 2003; 25(2):47-61. PubMed ID: 15124377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
    Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1091-9. PubMed ID: 18942671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of incentive-based formularies on drug utilization and spending.
    Sandy LG; Heady T
    N Engl J Med; 2004 Mar; 350(10):1057. PubMed ID: 15002122
    [No Abstract]   [Full Text] [Related]  

  • 24. The effects of cost sharing on the demand for prescription drugs in Belgium.
    van Doorslaer E
    Acta Hosp; 1984; 24(3):69-81. PubMed ID: 10268808
    [No Abstract]   [Full Text] [Related]  

  • 25. An industry in evolution.
    Blissenbach HF
    Med Interface; 1995 Oct; 8(10):80-1, 88. PubMed ID: 10152328
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparison of four contingent valuation methods to estimate the economic value of a pneumococcal vaccine in Bangladesh.
    Heinzen RR; Bridges JF
    Int J Technol Assess Health Care; 2008; 24(4):481-7. PubMed ID: 18828944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pricing and welfare implications of parallel imports in the pharmaceutical industry.
    Jelovac I; Bordoy C
    Int J Health Care Finance Econ; 2005 Mar; 5(1):5-21. PubMed ID: 15714261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Price elasticity and medication use: cost sharing across multiple clinical conditions.
    Gatwood J; Gibson TB; Chernew ME; Farr AM; Vogtmann E; Fendrick AM
    J Manag Care Spec Pharm; 2014 Nov; 20(11):1102-7. PubMed ID: 25351971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Out-of-pocket and total costs of fixed-dose combination antihypertensives and their components.
    Rabbani A; Alexander GC
    Am J Hypertens; 2008 May; 21(5):509-13. PubMed ID: 18437141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The economics of drug prescribing in Ireland.
    O'Hanrahan M; O'Malley K
    Ir Med J; 1981 Oct; 74(10):309-10, 312. PubMed ID: 7309452
    [No Abstract]   [Full Text] [Related]  

  • 31. The cost of medicine.
    Silk AD
    West J Med; 1990 Jan; 152(1):75-6. PubMed ID: 2309481
    [No Abstract]   [Full Text] [Related]  

  • 32. A DID analysis of the impact of health insurance reform in the city of Hangzhou.
    Zhang J
    Health Econ; 2007 Dec; 16(12):1389-402. PubMed ID: 17351883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
    Clark BE; Siracuse MV; Garis RI
    Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.
    Augurzky B; Göhlmann S; Gress S; Wasem J
    Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On using sample selection methods in estimating the price elasticity of firms' demand for insurance.
    Marquis MS; Louis TA
    J Health Econ; 2002 Jan; 21(1):137-45. PubMed ID: 11845921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic analysis of triptan therapy for acute migraine: a Medicaid perspective.
    Mullins CD; Subedi PR; Healey PJ; Sanchez RJ
    Pharmacotherapy; 2007 Aug; 27(8):1092-101. PubMed ID: 17655509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Recommendations of the German Society of Clinical Pharmacology and Therapy for implementing and evaluating pharmaco-economic studies].
    Brecht JG; Jenke A; Köhler ME; Harder S; Thürmann P; Rietbrock N
    Med Klin (Munich); 1995 Sep; 90(9):541-6. PubMed ID: 7476733
    [No Abstract]   [Full Text] [Related]  

  • 38. [Use of pharmacoeconomics analyses to health protection].
    Drozd M
    Wiad Lek; 2002; 55 Suppl 1():76-9. PubMed ID: 15002222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Demand for medical care in the urban areas of Iran: an empirical investigation.
    Kermani MS; Ghaderi H; Yousefi A
    Health Econ; 2008 Jul; 17(7):849-62. PubMed ID: 17990285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deductibles and health care expenditures: empirical estimates of price sensitivity based on administrative data.
    van Vliet RC
    Int J Health Care Finance Econ; 2004 Dec; 4(4):283-305. PubMed ID: 15467406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.